We claim:

1. A conjugate of hydrophilic polymers and the molecules from boxwood extraction or the synthetic derivatives of the molecules, represented by formula I:



(I)

wherein:

P is a hydrophilic polymer, which is selected from a group consisting of polyethylene glycol, polyglutamic acid, polyaspartatic acid, polypropylene, polyvinyl alcohol, polyacrylmorpholine and their copolymer thereof;

n is an integer, not exceed the total number of hydroxy and amine group on the D;

L is a linking group, which is selected from a group consisting of:, ester, carbonate, urethane, ether, acetal, and amide;

D is a molecule from the extraction of boxwood or its synthetic derivative, selected from a group consisting of Cyclovirobuxine D, Cycloprotobuxine A, Cycloprotobuxine C, Cyclovirobuxine C and their derivatives.

2. The conjugate of claim 1 wherein free hydroxyl on said hydrophilic polymer can be substituted by $C_{1\text{-}12}$ alkoxyl, cycloalkoxyl or aroxyl.

3. The conjugate of claim 1, wherein said, the hydrophilic polymer is polyethylene glycol, which has an average molecular weight from 300 to 60000.

4. A conjugate of claim 1, wherein said molecule from boxwood extraction is Cyclovirobuxine D, and the conjugate is represented by formula (I-D_1):



(I-D_1)

wherein:

P' is independently selected from H or P, but not all be H at the same time;

L is a linker group as disclosed previously.

5. The conjugate of claim 1, wherein said, the linkage between the hydrophilic polymer and the molecule is an ester linker.

6. The conjugate of claim 1, wherein said, the conjugate is selected from a group consisting of N,N'-di(α-methoxy-ω-carboxyl-polyethylene glycol)-Cyclovirobuxine D (1), α-methoxy-polyethylene-glycol-acetic-acid-Cyclovirobuxine D ester (4), and α-methoxy-ω-carboxyl-polyethylene glycol-glycin-Cyclovirobuxine D ester (7).

7. A conjugate of the hydrophilic polymer containing multicarboxyl oligopeptide and the molecules from boxwood extraction or the synthetic derivatives of the molecules, represented by formula (II)



(II)

wherein:

P is a hydrophilic polymer, which is selected from a group consisting of polyethylene glycol, polyglutamic acid, polyaspartatic acid, polypropylene, polyvinyl alcohol, polyacrylmorpholine and their copolymer thereof;

m is an integer from 2 to 12;
j is an integer from 1 to 6;

R_i is a group selected from H, $C_{1\text{-}12}$ alkyls, substituted aryls, aralkyls, heteroalkyls and substituted alkyls;

X is a linking group, selected from $(CH_2)_k$, $(CH_2)_kOCO$, $(CH_2)_kNHCO$ or $(CH_2)_kCO$, and k is 0-10;

Z is a linking group selected from O , NH, NHR, $O(CH_2)_hCOO$ or $NH(CHR)_hCOO$, and h is 1-10;

D is the molecule from extraction of boxwood or its synthetic derivatives, preferring Cyclovirobuxine D.

8. The conjugate of claim 7, wherein said, the hydrophilic polymer is polyethylene glycol, which has an average molecular weight from 300 to 60000.

9. The conjugate of claim 7, wherein said, the conjugate is selected form a group consisting of N-(α-methoxy-polyethylene glycol–ω-glu-glu)-Cyclovirobuxine D (2); N-(poly-glutamic-acid)-Cyclovirobuxine D (3); α-methoxy-polyethylene glycol–ω-glu-glu-glu)-Cyclovirobuxine D ester (5); poly-glutamic-acid-Cyclovirobuxine D ester (6); α-methoxy-ω-carboxyl-polyethylene glycol-ω-glu-glu -glycin-Cyclovirobuxine D ester(8), and poly-glutamic-acid- glycin Cyclovirobuxine D ester (9).

10. A composition comprising any conjugate of claim 1-9 and pharmaceutically acceptable carrier and excipient.

11. The composition of claim 10, wherein said composition may be formulated into therapeutic acceptable formular, including tablet, suppository, pill, soft and hard gelatin capsules, powder, solution, suspension and aerosol.